Marijuana (Herbs/Suppl)

Brand and Other Names:Cannabis, Ganja, more...Hash, Hashish, Hemp, Mary Jane, Pot, Reefer, Weed
  • Print

Suggested Dosing

Analgesia, Antiemetic, Appetite Stimulant, Glaucoma

Dosing of marijuana preparations is highly dependent on a variety of factors (eg, growing and harvesting conditions, plant parts isolated)

No standard guidelines exist for dosage ranges

Oral

  • Tincture: 5-15 drops or 1-3 drops of fluid extract

Inhalation

  • 1-3 grains (65-195mg) cannabis for smoking
  • Potency highly variable
  • Drug deteriorates rapidly

Wasting Syndrome (Orphan)

Treatment of HIV-associated wasting syndrome

Orphan indication sponsor

  • Multidisciplinary Association for Psychedelic Studies, Inc; 3 Francis St; Belmont, MA 02478
Next:

Suggested Uses

Decrease intraocular pressure, analgesia, antiemetic effects, appetite stimulant

Availability

The United States (US) Drug Enforcement Administration (DEA) classifies marijuana as a Schedule 1 substance under the Controlled Substances Act (CSA). Schedule I drugs are recognized as having a high potential for abuse with insufficient evidence for safety and efficacy with no currently accepted medical use for treatment in the US

Marijuana is not approved by the US Food and Drug Administration (FDA) for medical use in the US and remains classified as an illicit drug by the DEA. However, several states have adopted individual State Medical Marijuana Laws including: Alaska, California, Colorado, Hawaii, Maine, Maryland, Michigan, Montana, Nevada, New Mexico, Oregon, Rhode Island, Washington, and Vermont

In October of 2009 the US Justice Department announced that it will no longer enforce federal drug laws on persons who use marijuana for medicinal purposes or their sanctioned suppliers, as long as state laws are followed

Previous
Next:

Interactions

Interaction Checker

and Marijuana

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Tolerance

            Psychological or physical dependence

            Withdrawal symptoms

            Altered sensorium

            Dizziness

            Somnolence

            Fatigue

            Reduced coordination

            Cognitive impairment

            Impaired balance

            Euphoria

            Paranoia

            Hallucinations

            Mood alterations

            Panic

            Anxiety

            Hypotension

            Hypertension

            Tachycardia

            Flushing

            Syncope

            Xerostomia

            Nausea

            Vomiting

            Dysgeusia

            Tooth discoloration

            Anorexia

            Increased appetite

            Oral candidiasis

            Diarrhea

            Constipation

            Urinary retention

            Skin rash

            Dry eyes

            Blurred vision

            Allergy

            Cough

            Pharyngitis

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Coadministration with dronabinol (Cannabis derivative)

            Cautions

            History of substance abuse or mental illness

            Hepatic disease

            Cardiovascular disease

            Seizure disorders

            Nonpharmaceutical preparations contaminated with the fungus which may be hazardous to patients with compromised immune systems

            Geriatric patients

            Operating machinery or driving

            Drug interactions

            • May potenitate CNS depression w/ concomitant use with CNS depressants (eg, barbiturates, ethanol, anxiolytics, sedatives, and hypnotics, sedating H1-blockers, SSRIs, TCAs)
            • Use of marijuana with sedating anticholinergics may result in additive tachycardia and drowsiness
            • Other: cocaine, disulfiram, ethanol, protease inhibitors, sildenafil, theophylline, cyclophosphamide, doxorubicin
            • Cannabidiol, an inactive constituent of cannabis, may weakly inhibit cytochrome P450 enzymes (CYP1A2, 2C19, 2D6, & 3A4)
            • Cannabis is also a minor substrate for CYP2C9, 2C19, 2D6, 3A4
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            FDA pregnancy category not available; insufficient data regarding safety to fetus, avoid use

            Case-control study reported maternal use and childhood acute nonlymphoblastic leukemia (ANLL); Children’s Cancer Study Group report 10-fold increase of ANLL w/ maternal use (Robison et al, 1989; Briggs, 1998)

            Some sources found increased risk for low birth weight w/ maternal use

            Lactation

            THC found in Marijuana is reported to be concentrated and secreted into breast milk

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Absorption: 10-20% (inhaled); 1-10% (PO)

            Onset of action: 6-12 min (inhaled); 30-120 min (PO)

            Peak effect: 20-30 min (inhaled); 2-3 hrs (PO)

            Toxic dose (THC): 15 mg/kg; Lethal dose: 30 mg/kg

            Duration of effect: 2-6 hrs

            Vd: 10 L/kg (increases with chronic use)

            Protein Bound: 97-99%

            Metabolism: Hepatic hydroxylation to active and inactive metabolites, then further metabolized by alcohol dehydrogenase or alternatively, metabolites can be further oxidized to more polar compounds and glucuronide conjugates

            Excretion: Feces 30-50%; 10-16% excreted in the urine as metabolites

            Half-life: 28 hr (56 hr chronic use)

            Mechanism of Action

            Tetrahydrocannabinol (THC), a component of marijuana, acts both centrally and peripherally on endogenous cannabinoid receptors; activation of cannabinoid receptors affects serotonin release, increases catecholamines, inhibits parasympathetic activity, and inhibits prostaglandin biosynthesis

            Previous